You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent fallopian tube cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Prospective, Randomized Controlled Study of Cyclophosphamide,

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Shijiazhuang, Hebei, China
    Hebei
Aug 20, 2023

Cancer, Solid Tumor, Ovarian Cancer Trial in Minneapolis (FT538, Enoblituzumab)

Not yet recruiting
  • Cancer
  • +4 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Jan 24, 2023

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 26, 2022

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Denmark, Norway, Sweden (KAND567, Carboplatin)

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Odense, Denmark
  • +3 more
Oct 16, 2023

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

Recruiting
  • Recurrent Ovarian Cancer
  • +6 more
  • Durham, North Carolina
  • +2 more
Jul 26, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

Active, not recruiting
  • Fallopian Tube Endometrioid Tumor
  • +13 more
  • Orange, California
  • +19 more
Jan 10, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Beijing, Beijing, China
    Lingying Wu
Aug 22, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • New Haven, Connecticut
  • +1 more
Jan 11, 2023

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate

Recruiting
  • Ovarian Cancer
  • +2 more
  • MOv19-BBz CAR T cells
  • Alpha Folate Receptor expression test
  • Philadelphia, Pennsylvania
    University of Pennsylvania Health System
Sep 12, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion Trial in United States (metformin HCl, , Chemotherapy)

Suspended
  • Brenner Tumor
  • +27 more
  • metformin hydrochloride
  • +2 more
  • Birmingham, Alabama
  • +9 more
May 16, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022